Today: 9 June 2026
Gold Price Today Climbs Above $5,220 as Dollar Softens, Oil Slumps Ahead of U.S. CPI
10 March 2026
1 min read

Gold Price Today Climbs Above $5,220 as Dollar Softens, Oil Slumps Ahead of U.S. CPI

Bengaluru, March 10, 2026, 23:15 IST

Gold bounced back Tuesday, snapping out of its earlier slump as the dollar softened and the sharp drop in oil prices dialed back inflation concerns. Spot gold gained 1.7%, trading at $5,222.74 an ounce at 1514 GMT. April U.S. gold futures advanced 2.6% to $5,234.40. Silver jumped 2.8%, platinum moved up 2.4%, but palladium edged down 0.9%. According to Bart Melek at TD Securities, the pullback in oil is easing pressure on the Federal Reserve over rate cuts.

Gold’s bounce comes after the metal got knocked down on Monday by the reverse dynamic. With oil hovering close to $120 a barrel, inflation worries ramped up, the dollar strengthened, and bets on higher-for-longer U.S. rates mounted. Spot gold slid 1.5% to $5,091.62. Even so, Jim Wyckoff, senior analyst at Kitco Metals, notes that sustained conflict could keep a floor under prices as investors look for safety.

Oil was the first to shift. Prices plunged, with crude dropping over 10% on Tuesday after President Donald Trump floated the possibility of easing tensions in the Middle East. G7 energy ministers, for their part, held off on any emergency stockpile release, opting instead for the International Energy Agency to weigh alternatives. Brent slid $10.45 to $88.51 a barrel, while U.S. crude fell $10.61 to $84.16. That pullback helped relieve one of gold’s persistent drivers: worries that a spike in energy would push inflation higher.

Gold found some breathing space as the dollar slipped. The dollar index edged down 0.1% to 98.74. Michael Brown, senior research strategist at Pepperstone, noted that traders had been betting heavily on a rapid resolution to the conflict, but renewed clashes in Iran complicated those assumptions.

Attention shifts to U.S. inflation numbers next. The Labor Department will publish February’s Consumer Price Index at 8:30 a.m. ET on Wednesday—a release that could jolt rate forecasts if inflation runs above estimates.

The PCE price index lands Friday—the inflation metric the Fed keeps front and center. With policymakers not meeting again until March 17-18, gold traders face a tight stretch. Softer energy prices might offer some lift, but a hotter inflation number could wipe out Tuesday’s bounce.

Physical gold prices in Dubai aren’t tracking futures right now. Dealers in the city, a major route for bullion heading to India and other Asian destinations, reported discounts of $10 to $30 an ounce compared to London, with flight disruptions keeping metal stuck and buyers on the sidelines. MKS PAMP’s Nicky Shiels flagged the conflict’s “known unknowns” as a recipe for more volatility. Reuters

That’s the current risk. Across broader markets, traders are now betting the first Fed cut won’t happen until July. John Belton, portfolio manager at Gabelli Funds, pointed to a bigger issue: if rising oil prices start feeding into inflation expectations, it could derail the disinflation narrative—and any rebound in gold might not last long.

Stock Market Today

  • S&P 500 Rallies on Chipmaker Gains; Crude Oil Prices Retreat After Iran-Israel Ceasefire Signal
    June 9, 2026, 9:24 AM EDT. The S&P 500 gained +0.30% on Monday, driven by renewed investor interest in artificial intelligence boosting chipmakers. Nasdaq 100 rose +1.58%, while the Dow slipped -0.16%, dragged lower by Apple's -1% drop amid lukewarm AI platform feedback. Crude oil prices surged over +4% initially due to Iran-Israel tensions but retreated after Iran signaled an end to its current military operation. The market discounts a low 3% chance of a +25 basis point rate hike by the Federal Reserve on June 16-17. Treasury yields climbed, with 10-year notes reaching a two-week high of 4.58%, pressured by strong US jobs data and heavy upcoming Treasury auctions. Overseas markets closed mixed, with China's Shanghai Composite down -1.70% and Japan's Nikkei falling -3.85%.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Teradyne Sues China’s Elite Robots in Germany Over Universal Robots Software (Universal Robots)
Previous Story

Teradyne Sues China’s Elite Robots in Germany Over Universal Robots Software (Universal Robots)

Procter & Gamble Makes Nearly $1 Billion Gillette Boston HQ Bet as Growth Pressures Rise
Next Story

Procter & Gamble Makes Nearly $1 Billion Gillette Boston HQ Bet as Growth Pressures Rise

Go toTop